Ramiprilat is the active diacid metabolite of ramipril and belongs to the angiotensin-converting enzyme (ACE) inhibitor class. Ramipril is a prodrug that is converted to ramiprilat, the pharmacologically active metabolite responsible for ACE inhibition.
Ramiprilat is a dicarboxylic acid and dipeptide-related compound with established pharmaceutical and pharmacological significance. It inhibits ACE, reducing the conversion of angiotensin I to angiotensin II and thereby contributing to vasodilation and reduced blood pressure.
The established chemical identity of Ramiprilat is CAS 87269-97-4, with molecular formula C21H28N2O5 and molecular weight 388.46 g/mol.
Product Name: Ramiprilat
API Category: Cardiovascular API
Therapeutic Class: ACE Inhibitor
Drug Class: Angiotensin-Converting Enzyme Inhibitor
CAS Number: 87269-97-4
Molecular Formula: C21H28N2O5
Molecular Weight: 388.46 g/mol
PubChem CID: 5464096
ChEBI: CHEBI:77363
ChEMBL: CHEMBL1201365
Synonyms: Ramiprilate, Ramipril Diacid, HOE 498 Diacid, Ramiprilatum
Parent Drug: Ramipril
Ramiprilat is identified by PubChem and IUPHAR as the active metabolite of ramipril.
Ramiprilat is the diacid form generated from ramipril following hydrolysis of the ethyl ester group. Its molecular structure contains a cyclopenta[b]pyrrole-derived ring system, peptide-like amide functionality, a phenylpropyl group and two carboxylic acid groups.
Ramiprilat has a molecular weight of 388.46 g/mol and an exact mass of 388.199822 Da. PubChem reports an XLogP3 value of 0.7, hydrogen-bond donor count of 3, hydrogen-bond acceptor count of 6, and 8 rotatable bonds.
The compound has multiple defined stereocenters consistent with its specific stereochemical pharmaceutical structure.
Ramiprilat is primarily recognized as the pharmacologically active metabolite of ramipril and is associated with ACE-inhibitor pharmacology.
Its pharmaceutical relevance includes:
Ramiprilat has also been investigated directly as an ACE inhibitor in pharmacological research.
Ramiprilat inhibits angiotensin-converting enzyme (ACE), an enzyme involved in the conversion of angiotensin I to the potent vasoconstrictor angiotensin II.
By reducing angiotensin II formation, ACE inhibition decreases vasoconstrictor activity and reduces aldosterone-related effects. This contributes to vasodilation and reduction of blood pressure.
Ramiprilat is the active metabolite responsible for the ACE-inhibitory activity of ramipril.
Ramiprilat API quality assessment can include identity, assay, related substances, water content, residual solvents and other applicable pharmaceutical quality attributes.
Analytical control may include:
No universal USP-NF release specification for Ramiprilat was identified in the authoritative sources reviewed for this page. Therefore, numerical API release limits such as assay, individual impurities, total impurities, water and residue on ignition should be treated as product-specific/specification-dependent rather than presented as universal pharmacopoeial limits.
Ramiprilat API manufacturing requires controlled chemical processing to obtain the diacid active ingredient with appropriate stereochemical purity and impurity control.
Manufacturing controls may include:
The manufacturing process should be supported by validated analytical methods and a suitable impurity-control strategy.
| Property | Value |
|---|---|
| Product | Ramiprilat |
| CAS Number | 87269-97-4 |
| Molecular Formula | C21H28N2O5 |
| Molecular Weight | 388.46 g/mol |
| PubChem CID | 5464096 |
| Appearance | White to off-white solid |
| XLogP3 | 0.7 |
| Exact Mass | 388.199822 Da |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 8 |
| Stereochemistry | Defined stereochemical structure |
| Solubility | Limited water solubility; solvent-specific |
| Melting Point | 139–141°C reported for reference material; not established as a universal pharmaceutical release criterion |
The molecular and computed physicochemical data are supported by PubChem. The 139–141°C melting-point value is reported by a commercial chemical-information source and should therefore not be treated as a universal API specification.
Ramiprilat API should be packaged in suitable pharmaceutical-grade containers that protect the material from contamination, moisture and inappropriate environmental exposure.
The final storage condition for bulk API should be established according to validated stability data and the approved product specification.
For reference-grade commercial Ramiprilat, storage at controlled low temperature has been reported by suppliers; this should not automatically be adopted as the finished API storage specification without supporting stability data.
Typical pharmaceutical API documentation may include:
Ramiprilat requires controlled manufacturing and analytical characterization because it is a stereochemically defined active ACE-inhibitor metabolite with multiple carboxylic acid functionalities.
A qualified Ramiprilat API Manufacturer in India should maintain appropriate controls over raw materials, synthesis, hydrolysis, purification, stereochemical quality, drying, analytical testing and batch documentation.
Product-specific specifications should be established according to the intended pharmaceutical application, validated analytical methods and applicable regulatory requirements.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | NLT 98.0% by HPLC |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Heavy Metals | NMT 10 ppm |
| Individual Impurity | NMT 0.10% |
| Total Impurities | NMT 0.50% |
| Water Content | NMT 1.0% |